GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

3.365 +0.085 (+2.59%)

Delayed Quote Updated: 3:20 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Why GoodRx Stock Was Plunging Today ↗

November 09, 2022

Revenue continued to slide at the healthcare company.

Via The Motley Fool

Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session ↗

November 09, 2022

Gainers

Via Benzinga

GoodRx Holdings, Inc. (GDRX) Q3 2022 Earnings Call Transcript ↗

November 08, 2022

GDRX earnings call for the period ending September 30, 2022.

Via The Motley Fool

10 Analysts Have This to Say About GoodRx Holdings ↗

November 04, 2022

Within the last quarter, GoodRx Holdings (NASDAQ:GDRX) has observed the following analyst ratings:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 09, 2022

Gainers Merrimack Pharmaceuticals (NASDAQ:MACK) shares rose 180.0% to $11.2 during Wednesday's pre-market session. The company's market cap stands at $150.1 million. As per the news, the Q3 earnings...

Via Benzinga

GoodRx Reports Third Quarter 2022 Results

November 08, 2022

From GoodRx Holdings, Inc.

Via Business Wire

Where GoodRx Holdings Stands With Analysts ↗

November 04, 2022

Over the past 3 months, 10 analysts have published their opinion on GoodRx Holdings (NASDAQ:GDRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

New Report from GoodRx Shows Positive Impact of Giving Pharmacists the Power to Prescribe

November 03, 2022

From GoodRx

Via Business Wire

Expert Ratings for GoodRx Holdings ↗

October 11, 2022

GoodRx Holdings (NASDAQ:GDRX) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗

November 04, 2022

Upgrades

Via Benzinga

GoodRx to Present at Upcoming Investor Conferences

October 27, 2022

From GoodRx Holdings, Inc.

Via Business Wire

Should You Buy the Nasdaq's 4 Worst-Performing Stocks of 2022? ↗

October 16, 2022

These four tech stocks are down nearly 90%.

Via The Motley Fool

Before Pushing Others At Work, Take A Look In The Mirror ↗

October 14, 2022

Leaders often see their job as driving greatness from others. But the first step is developing your own leadership style.

Via Investor's Business Daily

GoodRx Announces Provider Mode, An Innovative Experience Built Specifically for Healthcare Providers

October 13, 2022

From GoodRx

Via Business Wire

GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®

October 13, 2022

From GoodRx

Via Business Wire

GoodRx Announces Date for Third Quarter 2022 Earnings Release and Conference Call

October 11, 2022

From GoodRx Holdings Inc.

Via Business Wire

Alphabet To $134? Plus This Analyst Slashes Price Target On McDonald's ↗

October 11, 2022

Credit Suisse cut the price target on Alphabet Inc. (NASDAQ: GOOGL) from $140 to $134. Credit Suisse analyst Stephen Ju maintained an Outperform rating on the stock. Alphabet shares fell 1.2% to $96.69...

Via Benzinga

Where GoodRx Holdings Stands With Analysts ↗

October 11, 2022

Over the past 3 months, 11 analysts have published their opinion on GoodRx Holdings (NASDAQ:GDRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

GoodRx Offers Free Telehealth Appointments to Florida Residents Affected by Hurricane Ian

October 04, 2022

From GoodRx

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022 ↗

September 16, 2022

Via Benzinga

What 14 Analyst Ratings Have To Say About GoodRx Holdings ↗

September 07, 2022

Over the past 3 months, 14 analysts have published their opinion on GoodRx Holdings (NASDAQ:GDRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022 ↗

September 07, 2022

Upgrades

Via Benzinga

GoodRx to Present at the Goldman Sachs Communacopia + Technology Conference

August 29, 2022

From GoodRx Holdings, Inc.

Via Business Wire

Looking Into GoodRx Holdings's Return On Capital Employed ↗

August 29, 2022

GoodRx Holdings (NASDAQ:GDRX) brought in sales totaling $191.80 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 111.51%, resulting in a loss of $1.42 million.

Via Benzinga

This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday ↗

August 18, 2022

Gainers

Via Benzinga

GoodRx Holdings, Inc. (NASDAQ: GDRX) Investor Alert: Investigation over Potential Wrongdoing ↗

August 15, 2022

San Diego, CA -- (SBWIRE) -- 08/15/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at GoodRx Holdings, Inc.

Via SBWire

The Most Expensive Drug From Novartis Associated With Two Deaths: Report ↗

August 12, 2022

Two children with spinal muscular atrophy have died after receiving Novartis AG's (NYSE: NVS) Zolgensma, a one-time gene therapy, spotlighting its risks and questioning the safety of genetic medicines...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022 ↗

August 12, 2022

Via Benzinga

WeTrade, Roblox And Some Other Big Stocks Moving Lower On Wednesday ↗

August 10, 2022

OptimizeRx Corporation (NASDAQ: OPRX) shares fell 26.7% to $16.32 after the company reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.

Via Benzinga

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session ↗

August 09, 2022

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.